Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus brevis
- Development stage
- Preclinical
- Lead developer
- CD Investments
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus brevis is a probiotic bacterium known for its ability to produce lactic acid and its diverse beneficial effects on human and animal health. It modulates both gut and oral microbiota, influences the gut-brain axis, and produces metabolites such as Gamma Amino Butyric Acid (GABA) and butyric acid, which contribute to neuroprotective, anti-inflammatory, and antioxidant activities. This bacterium is being investigated for its potential in treating conditions such as depression, mucositis, chronic periodontitis, dental caries, non-alcoholic fatty liver, and secondary bacterial pneumonia in severe COVID-19 patients. It also shows promise in promoting oral health, mitigating cisplatin-induced cardiotoxicity, and improving livestock performance under heat stress.
- Other names
- Levilactobacillus brevis
02
Targets
ADI (Arginine deiminase)
Beyond the preview
Go deeper on lactobacillus brevis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus brevis.